Study Supports Tamoxifen for DCIS Early Breast Cancers
MONDAY, Dec. 16, 2024 (HealthDay News) — The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast cancer, a new study says. Women who took tamoxifen after undergoing a lumpectomy to remove ductal carcinoma in situ (DCIS)Continue Reading